vedolizumab,ustekinumab
takeda,janssen
[]
emily wright on vdz &amp; ust in pregnancy and infants -prospective study
-n=102 (58vdz), most monotherapy
-25% clin active (vdz=ust)
-ust stable, vdz in (no clin impact)
-ust median clearance 14wks
-vdz median clearance 11wks
- risk minor infx in on ust
#ddw2023
Physician-Scientist. Gastroenterology. Epidemiology. Microbiome/host response. @KiraNewmanMDPhD@med-mastodon.com 🏳️‍🌈 she/her